AND EXCHANGE COMMISSION
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
SECURITIES EXCHANGE ACT OF 1934
For the month of September 2019
Commission File Number: 001-31995
(Translation of registrant's name into English)
2-1250 Waverley Street
Winnipeg, MB Canada R3T 6C6
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x
Form 40-F o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether the registrant
by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.
If “Yes” is marked, indicate below
the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72____.
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Date: September 30, 2019
||/s/ Dr. Albert D. Friesen |
||Dr. Albert D. Friesen|
||Title: President & CEO|
Medicure Announces Acquisition Of Full
United States Ownership Of Zypitamag™
WINNIPEG, Sept. 30, 2019 /CNW/ - Medicure Inc.
("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to
announce that through its subsidiary, Medicure International Inc., it has acquired the ownership of ZYPITAMAGTM (pitavastatin)
tablets, from Cadila Healthcare Ltd., India ("Zydus") for US and Canadian markets. Under terms of the agreement, Zydus
will receive an upfront payment of U.S. $5,000,000 and U.S. $2,000,000 in deferred payments to be made over the next four years,
as well as contingent payments on achievement of milestones and royalties related to net sales.
Medicure previously had acquired U.S. marketing
rights with a profit-sharing arrangement. With this acquisition Medicure retains all profits, with full control of marketing and
ZYPITAMAGTM is a HMG-CoA reductase
inhibitor indicated for adult patients with primary hyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet, to reduce
elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and
to increase high-density lipoprotein cholesterol (HDL-C) (see additional safety information provided below).
ZYPITAMAGTM was approved in 2017
by the U.S. Food and Drug Administration for sale and marketing in the United States and was launched by Medicure in the second
quarter of 2018 through a license agreement it had entered into with Zydus.
"This acquisition of ZYPITAMAGTM fits
well with Medicure's mission of being a significant cardiovascular company focused on the U.S. market," commented Medicure's
CEO, Dr. Albert D. Friesen. "We look forward to growing the ZYPITAMAGTM brand as part of our portfolio of
Important Safety Information for ZYPITAMAGTM
Indications and Usage
Drug therapy should be one component of multiple-risk-factor
intervention in individuals who require modifications of their lipid profile. Lipid-altering agents should be used in addition
to a diet restricted in saturated fat and cholesterol only when the response to diet and other nonpharmacological measures has
Primary Hyperlipidemia and Mixed Dyslipidemia: Zypitamag™
is indicated as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C),
apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with
primary hyperlipidemia or mixed dyslipidemia.
Limitations of Use: Doses of Zypitamag™
greater than 4 mg once daily were associated with an increased risk for severe myopathy in premarketing clinical studies. Do not
exceed 4 mg once daily dosing of Zypitamag™. The effect of Zypitamag™ on cardiovascular morbidity and mortality has
not been determined. Zypitamag™ has not been studied in Fredrickson Type I, III, and V dyslipidemias.
Zypitamag™ is contraindicated in
patients with a known hypersensitivity to product components, in patients with active liver disease (which may include unexplained
persistent elevations in hepatic transaminase levels), in women who are pregnant or may become pregnant, in nursing mothers or
in coadministration with cyclosporine.
WARNINGS & PRECAUTIONS
Skeletal Muscle Effects: Cases of myopathy
and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including
- These risks can occur at any dose level, but increase in
a dose-dependent manner, with advanced age (≥ 65 years), renal impairment, and inadequately treated hypothyroidism; administer
with caution in these patients, or when used concomitantly with fibrates or lipid-modifying doses of niacin, or colchicine. Avoid
concomitant administration with gemfibrozil.
- Advise patients to promptly report unexplained and/or persistent
muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever; discontinue Zypitamag™.
- If muscle signs and symptoms persist after discontinuation,
this may be a sign of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy associated with statin use, requiring
immediate medical attention. IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase, which persist
despite discontinuation of statin treatment; muscle biopsy showing necrotizing myopathy without significant inflammation; improvement
with immunosuppressive agents.
- Zypitamag™ should be discontinued if markedly elevated
creatine kinase levels occur or myopathy is diagnosed or suspected.
- Zypitamag™ should also be temporarily withheld in
any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary
to rhabdomyolysis (e.g., sepsis, hypotension, dehydration, major surgery, trauma, severe metabolic, endocrine, and electrolyte
disorders, or uncontrolled seizures).
Liver Enzyme Abnormalities:
- Persistent elevation in hepatic transaminases can occur.
Check liver enzymes before initiating therapy and if signs or symptoms of liver injury occur; advise patients to report fatigue,
anorexia, right upper abdominal discomfort, dark urine or jaundice.
- Fatal and non-fatal hepatic failure can occur. Interrupt
Zypitamag™ if serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs. If an alternate etiology
is not found do not restart Zypitamag™.
- Use Zypitamag™ with caution in patients who consume
substantial quantities of alcohol and/or have a history of chronic liver disease. Do not use Zypitamag™ if patient has active
liver disease, which may include unexplained persistent transaminase elevations.
- Increases in HbA1c and fasting serum glucose levels have
COMMON ADVERSE REACTIONS
Myalgia, back pain, diarrhea, constipation
and pain in extremity (rate ≥ 2% in at least one marketed dose). This is not a complete list of all reported adverse events.
For additional information, refer to full Prescribing
You are encouraged to report negative side
effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
Medicure is a pharmaceutical company focused
on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the
marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAGTM (pitavastatin)
tablets and the ReDS™ device in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma
Inc. For more information on Medicure please visit www.medicure.com.
To be added to Medicure's e-mail list, please
Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward Looking Information: Statements
contained in this press release that are not statements of historical fact, including, without limitation, statements containing
the words "believes", "may", "plans", "will", "estimates", "continues",
"anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking
information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information
and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking
statements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perception
of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and
reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors
beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are
cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's future
product revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical
trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence
upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change
in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited
to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign
exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals
for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or
research and development projects, or the availability of financing on reasonable terms; results of current and future clinical
trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list
of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise
any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional
discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings
with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk
Factors" section of its Form 20F for the year ended December 31, 2018.
View original content:http://www.prnewswire.com/news-releases/medicure-announces-acquisition-of-full-united-states-ownership-of-zypitamag-300927426.html
SOURCE Medicure Inc.
View original content: http://www.newswire.ca/en/releases/archive/September2019/30/c2921.html
For further information: James Kinley, Chief Financial Officer,
Tel. 888-435-2220, Fax 204-488-9823, E-mail: firstname.lastname@example.org, www.medicure.com
CO: Medicure Inc.
CNW 06:30e 30-SEP-19
This regulatory filing also includes additional resources: